ClinicalTrials.gg
Not yet recruitingNCT07584798Updated Sep 17, 2026

Self-Monitoring OCT

An interventional study of Self-administered OCT imaging system and Technician-acquired OCT imaging in Obtaining OCT (Optical Coherence Tomography) Images, sponsored by Case Western Reserve University. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-17.

Sponsored by Case Western Reserve University · Not applicable, Interventional, and Health services research

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this research study is to test participants ability to obtain OCT images of the eyes using an OCT device that is comparable to FDA-approved OCT devices on the market, without the help of an eye technician. Patients with ocular diseases often need to come to frequent appointments with an eye care provider for close monitoring and evaluation. Transportation difficulties, other medical problems, and limited appointments slots can make regular follow-up challenging. In addition, the anxiety of permanent vision loss and subjective nature of monitoring symptoms highlight the need for an alternative solution in which patients can self-generate OCT images of the eye for the eye care provider to review.

02

Conditions studied

  • Obtaining OCT (Optical Coherence Tomography) Images

Keywords

  • Ocular diseases
  • Eye care provider
  • Self monitoring
03

In context

Lead sponsor

Case Western Reserve University is the lead sponsor of 160 studies on the registry; 28 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 7 (70%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Provision of signed and dated .
  • 2. Age ≥ 18 years.
  • 3. Presenting for care at a University Hospitals Eye Institute clinic
  • 4. Willing to complete study questionnaires.
  • 5. Scheduled to undergo standard technician-acquired OCT

Exclusion criteria

Exclusion Criteria:

  • 1. Unable to provide or, in the judgment of study staff, unable to understand study procedures.
  • 2. Unable to cooperate with imaging or maintain stable positioning such that an evaluable OCT scan cannot be obtained (e.g., severe tremor or inability to maintain head position).
  • 3. Facial skin condition or open wound at the points of device contact that would make use of the headrest unsafe.
  • 4. Acute medical or ocular condition requiring immediate evaluation that, in the PI's judgment, precludes participation at that time.
  • 5. Any other condition that, in the opinion of the PI/designee, would place the participant at undue risk or compromise data quality (documented).
  • 6. Patients with visual acuity \<20/200.
  • 7. Patients with significant media opacities precluding an OCT scan (posterior subcapsular cataract, vitreous hemorrhage, etc), or severe ptosis.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Self-administered OCT Images

    Participants will use an OCT device to obtain OCT images of the eyes.

    Procedure: Self-administered OCT imaging system

  • Active comparator
    Technician-acquired OCT

    Technicians will use a standard OCT device to obtain OCT images of the eyes as per standard of care.

    Procedure: Technician-acquired OCT imaging

Interventions

  • ProcedureSelf-administered OCT imaging system

    Self-administered OCT imaging using modified portable OCT with headrest and software workflow to enable patient self-operation and secure image transfer to a remote reading center.

  • ProcedureTechnician-acquired OCT imaging

    Technician-acquired OCT obtained using routine clinical equipment during the same visit

06

What researchers measure

Primary outcomes

  1. Number of inner retinal abnormalities detected as measured by OCT images

    Time frame: through study completion, an average of 1 year

  2. Number of outer retinal abnormalities detected as measured by OCT images.

    Time frame: through study completion, an average of 1 year

  3. Sensitivity as measured by OCT images.

    Time frame: through study completion, an average of 1 year

  4. Specificity as measured by OCT images.

    Time frame: through study completion, an average of 1 year

  5. Positive predictive value (PPV) as measured by OCT images.

    Time frame: through study completion, an average of 1 year

  6. Negative predictive value (NPV) as measured by OCT images.

    Time frame: through study completion, an average of 1 year

Secondary outcomes

  1. Image-quality as recorded by nurse coordinator during patient interaction with the device.

    Time frame: through study completion, an average of 1 year

  2. Number of successful completion of self-scans as recorded by nurse coordinator during patient interaction with the device.

    Time frame: through study completion, an average of 1 year

  3. Number of repeated attempts

    Time frame: through study completion, an average of 1 year

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2026; primary completion for Dec 2027, 15 months later.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2026
First posted
May 13, 2026
StartEst.
Sep 2026
Primary completionEst.
Dec 15, 2027
CompletionEst.
Dec 15, 2027
Last update
Sep 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07584798
Responsible party
Warren Sobol (Physician, Case Western Reserve University) — Principal investigator
First posted
May 13, 2026
Start date
Sep 2026 (estimated)
Primary completion
Dec 15, 2027 (estimated)
Completion
Dec 15, 2027 (estimated)
Last update
Sep 17, 2026

Study contacts

Warren Sobol, MD
principal investigator · University Hospitals Cleveland Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion